标题
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-12-12
DOI
10.3389/fonc.2018.00608
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
- (2018) L Malorni et al. ANNALS OF ONCOLOGY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
- (2017) Erik S. Knudsen et al. Oncotarget
- CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
- (2017) Juliann E. Kosovec et al. Oncotarget
- Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
- (2016) Myrella Vlenterie et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib
- (2016) Mark A. Dickson et al. JAMA Oncology
- Innovative Clinical Trials: The LUNG-MAP Study
- (2015) CE Steuer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
- (2015) Marco Perez et al. Oncotarget
- Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.
- (2014) Jack A. Dempsey et al. CANCER RESEARCH
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
- (2014) S. C. Tate et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6
- (2014) Xiao Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling
- (2014) Miriam Potrony et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.
- (2014) S. Kim et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
- (2014) Y.-X. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
- (2013) Mark A. Dickson et al. JOURNAL OF CLINICAL ONCOLOGY
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells
- (2012) Yiwei Lin et al. FEBS LETTERS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
- (2011) Aimee M Crago et al. CURRENT OPINION IN ONCOLOGY
- The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors
- (2011) Caroline Louis-Brennetot et al. GENES CHROMOSOMES & CANCER
- Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network
- (2011) Martin Dreyling et al. LEUKEMIA & LYMPHOMA
- Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer
- (2011) Abla A. Abou-Zeid et al. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Reexpression of hSNF5 in Malignant Rhabdoid Tumor Cell Lines Causes Cell Cycle Arrest through a p21CIP1/WAF1-Dependent Mechanism
- (2010) Y. Kuwahara et al. CANCER RESEARCH
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- (2010) Jordi Barretina et al. NATURE GENETICS
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors
- (2009) E. M. Jackson et al. CLINICAL CANCER RESEARCH
- Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma
- (2008) J. J. Molenaar et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search